TCDA

Tricida, Inc. Common Stock
TCDA

Delisted

TCDA was delisted on the 23rd of January, 2023.

Back to rankings
 

About: Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.

Employees: 57

Healthcare Drug Manufacturers - General

Financial journalist opinion

Neutral
Business Wire
1 year ago
SierraConstellation Partners Receives Industry Recognition for Work with Tricida
LOS ANGELES--(BUSINESS WIRE)--SierraConstellation Partners (“SCP”), a national interim management and advisory firm, has been awarded top industry accolades for the firm's work on the restructuring of Tricida, Inc. (“Tricida”), a clinical-stage pharmaceutical company focused on the development and commercialization of a drug for the treatment of chronic kidney disease. SCP was awarded: The M&A Advisor Turnaround Award for Healthcare/Life Sciences Deal of the Year (Over $100MM) The M&A A.
SierraConstellation Partners Receives Industry Recognition for Work with Tricida
See News Rankings
Charts implemented using Lightweight Charts™